CC
Casdin Capital Portfolio holdings
AUM $1.1B
1-Year Return
24.98%
This Quarter Return
+71.3%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$910M
AUM Growth
+$326M
(+56%)
Cap. Flow
+$44.1M
Cap. Flow
% of AUM
4.85%
Top 10 Holdings %
Top 10 Hldgs %
64.43%
Holding
33
New
2
Increased
10
Reduced
4
Closed
4
Top Buys
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$25.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$18.5M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$16.7M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
+$14M |
| 5 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$11.4M |
Top Sells
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$50.4M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$7.42M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$5.79M |
| 4 |
NVTA
Invitae Corporation
NVTA
|
+$4.68M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$3.19M |
Sector Composition
| 1 | Healthcare | 79.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
CareDx
CDNA
$755M
| $6.3M | 0.69% |
200,000
| – | – |
|
27
Alector
ALEC
$279M
| $6.2M | 0.68% |
+331,039
| New | +$6.2M |
|
28
Gilead Sciences
GILD
$138B
| $5.2M | 0.57% |
+80,000
| New | +$5.2M |
|
29
Denali Therapeutics
DNLI
$1.94B
| $2.32M | 0.26% |
100,000
| – | – |
|
|
30
iShares Biotechnology ETF
IBB
$5.67B
| – | – |
-60,000
| Closed | -$5.79M |
|
|
QTNT
31
DELISTED
Quotient Limited Ordinary Shares
QTNT
| – | – |
-8,125
| Closed | -$1.99M |
|
|
NTGN
32
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| – | – |
-263,344
| Closed | -$1.33M |
|
|
LOXO
33
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-360,000
| Closed | -$50.4M |
|